‘Innovative’ PKU treatment launched in UK
PKU is a rare, inherited metabolic disorder that affects approximately 70 babies each year in the UK.
Read More
Tag: Phenylketonuria
EU approval for Palynziq in adult phenylketonuria
It’s the first substitution therapy approved in Europe to target the underlying cause of PKU by helping the body to break down Phe.
Read More
US clears first enzyme therapy for PKU
Biomarin’s Palynziq has been approved as the first enzyme therapy to treat the rare brain-threatening genetic disease phenylketonuria (PKU) in adults in the US.
Read More
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
